Palliative Treatment of Metastatic Colorectal Cancer: What is the Optimal Approach?

Strickler, John H.; Hurwitz, Herbert I.

doi:10.1007/s11912-013-0363-z

Cited by 9 publications

(8 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[49] Bevasizumab içeren tedavi rejimleri NCCN klavuzunda birinci basamak tedavide öneri olarak yer almaktadır. [50] Yine VEGF trap olarak adlandırılan ziv-aflibercept de NCCN klavuzunda ikini basamak tedavide irinotekan içeren kemoterapi rejimleri ile kombine kullanımda öneri olarak yer almaktadır. [50] Her ne kadar tedavi kılavuzlarında yer almasa da metronomik kemoterapi uygulamalarında, kemoterapi ilaçlarının düşük dozlarda kullanılması ile başta VEGF olmak üzere bazı anjiyogenik moleküllerin sentezinin ve salgısının baskılanabildiği gösterilmiştir.…”

Section: Tirozin Kinaz İnhibitörlerinin Kolorektal Kanserde Kullanımıunclassified

“…[50] Yine VEGF trap olarak adlandırılan ziv-aflibercept de NCCN klavuzunda ikini basamak tedavide irinotekan içeren kemoterapi rejimleri ile kombine kullanımda öneri olarak yer almaktadır. [50] Her ne kadar tedavi kılavuzlarında yer almasa da metronomik kemoterapi uygulamalarında, kemoterapi ilaçlarının düşük dozlarda kullanılması ile başta VEGF olmak üzere bazı anjiyogenik moleküllerin sentezinin ve salgısının baskılanabildiği gösterilmiştir. [51] Daha önce yaptığımız bir çalışma-da kolorektal kanser tedavisinde kullanılan 5-fluorourasil, oksaliplatin ve irinotekanın tümör hücre-lerini öldürmeyen düşük dozlarında in-vitro olarak VEGF yapımını baskıladığını göstermiştik.…”

Section: Tirozin Kinaz İnhibitörlerinin Kolorektal Kanserde Kullanımıunclassified

See 1 more Smart Citation

Angiogenesis and anti-angiogenic treatments in colorectal cancer

Aktaş¹

2014

TJ Oncol

View full text Add to dashboard Cite

Angiogenesis is extremely important in cancer progression. The therapeutic approaches that target regression of tumors through suppression of angiogenesis have been under investigation for a long time. In addition to chemotherapy, monotherapy as well as monoclonal antibodies and tyrosine kinase inhibitors increase the survival of patients with colorectal cancer. Considering this point of view, understanding the intrinsic molecular mechanisms will afford great opportunity to develop targeted therapies to combat colorectal cancer.

show abstract

Section: Tirozin Kinaz İnhibitörlerinin Kolorektal Kanserde Kullanımıunclassified

Angiogenesis and anti-angiogenic treatments in colorectal cancer

Aktaş¹

2014

TJ Oncol

View full text Add to dashboard Cite

show abstract

“…Colorectal cancer (CRC) remains one of the most common malignancies with over 600,000 deaths annually in the global . Even more distressing, around 25% of CRC cases are diagnosed with lung or liver metastases , which is responsible for CRC recurrence and has brought a huge challenge for our current CRC treatment .…”

Section: Introductionmentioning

confidence: 99%

Weichang'an suppressed migration and invasion of HCT116 cells by inhibiting Wnt/β‐catenin pathway while upregulating ARHGAP25

Zheng

et al. 2019

Biotech and App Biochem

View full text Add to dashboard Cite

Evidence suggests that Weichang'an (WCA) inhibited the metastasis of colorectal cancer (CRC) in vitro and downregulates oncogenic β‐catenin; more intriguingly, we also found an upregulation of ARHGAP25 in this process. This study aimed to investigate the mechanisms by which WCA regulated CRC metastasis in vitro. Here, HCT116 cells were transfected with siRNAs to interfere ARHGAP25 expression. WCA decoction, XAV939 (a specific Wnt/β‐catenin pathway inhibitor), and LiCl (an activator for Wnt/β‐catenin pathway) were used for treatment. Cell migratory and invasive capacities were determined using Transwell chamber. The activation of Wnt/β‐catenin pathway was assessed by determining the expression of MMP7, MMP9, ZEB1, and β‐catenin. The study suggests that WCA inhibited the migration and invasion of HCT116 cells and suppressed the activation of Wnt/β‐catenin pathway, as evidenced by retarding MMP7, MMP9, ZEB1, and β‐catenin. However, siRNA–ARHGAP25 resulted in the opposite. In siRNA–ARHGAP25‐transfected HCT116 cells, WCA (0.4 mg/mL) induced the antimetastatic effects and the inactivation of Wnt/β‐catenin pathway was remarkably reversed with additional LiCl treatment. Our study concludes that inhibiting Wnt/β‐catenin pathway while promoting ARHGAP25 was the mechanism, whereby WCA retarded migration and invasion of CRC in vitro.

show abstract

“…Colorectal cancer (CRC) is a major risk to human health. Although the mortality rates of patients with CRC have gradually declined with the improvement of medical standards, CRC remains the third major cancer worldwide, and the mortality rate for CRC ranks second among known malignancies [1][2][3]. At present, surgical resection and systematic chemotherapy are the main treatment options for CRC.…”

Section: Introductionmentioning

confidence: 99%

Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12

et al. 2019

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a common malignant tumor in the digestive tract, and 30%-85% of CRCs express epidermal growth factor receptors (EGFRs). Recently, treatments using cetuximab, also named C225, an anti-EGFR monoclonal antibody, for CRC have been demonstrated to cause an S492R mutation in EGFR. However, little is known about the biological function of S492R EGFR. Therefore, we attempted to elucidate its biological function in CRC cells and explore new treatment strategies for this mutant form. Our study indicated that EGFR and S492R EGFR accelerate the growth of CRC cells in vitro and in vivo and monoclonal antibody CH12, which specifically recognizes an EGFR tumor-specific epitope, can bind efficiently to S492R EGFR. Furthermore, mAb CH12 showed significantly stronger growth suppression activities and induced a more potent antibody-dependent cellular cytotoxicity effect on CRC cells bearing S492R EGFR than mAb C225. mAb CH12 obviously suppressed the growth of CRC xenografts with S492R EGFR mutations in vivo. Thus, mAb CH12 may be a promising therapeutic agent in treating patients with CRC bearing an S492R EGFR mutation.

show abstract

Palliative Treatment of Metastatic Colorectal Cancer: What is the Optimal Approach?

Cited by 9 publications

References 67 publications

Angiogenesis and anti-angiogenic treatments in colorectal cancer

Angiogenesis and anti-angiogenic treatments in colorectal cancer

Weichang'an suppressed migration and invasion of HCT116 cells by inhibiting Wnt/β‐catenin pathway while upregulating ARHGAP25

Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12

Contact Info

Product

Resources

About